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Abstract
Background: The purpose of our study was to determine the prevalence and significance of
psammoma bodies (PBs) in the cervicovaginal smears of the screening population of Trento district
(Italy), with the description of the cytological presentation of an asymptomatic bilateral ovarian
psammocarcinoma.
Methods: From 1993 to 2006, women with PBs detected on consecutively screened cervical
smears were identified from the computerized pathology database of Rovereto Hospital. The
follow-up period was set from the time of cytological diagnosis to May 31st, 2007. Clinical
information was obtained from retrospective review of women's medical records. The source of
PBs was identified with adequate diagnostic procedures.
Results: PBs were found in six of the 201,231 Papanicolaou screening smears (0.0029%). Benign
conditions (intrauterine device, inclusion ovarian cysts and ovarian cystoadenofibroma with PBs)
were found in four patients. In two cases, PBs were associated with malignant cells; a bilateral
ovarian malignancy was diagnosed in both cases, a serous adenocarcinoma and a
psammocarcinoma.
Conclusion: PBs in the cervicovaginal smears are a rare finding, associated more often with benign
conditions than with malignancies. Moreover, to our knowledge, our case of primary ovarian
psammocarcinoma is the first report in which the presence of malignant cells and PBs in the
cervicovaginal and endometrial smears represents the first manifestation of disease.
Background
The presence of psammoma bodies (PBs) in cervicovagi-
nal smears (CVS) is a rare finding, the prevalence ranging
from 0.00047% to 0.057% in large series studies [1-6].
PBs on Papanicolau smears have been described in associ-
ation with a wide variety of gynaecological conditions
including malignant tumors, such as malignant serous
epithelial ovarian tumors [7], endometrial carcinoma
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with PBs [8], neuroendocrine carcinoma of the cervix [9],
primary peritoneal borderline tumour [10], tubal serous
carcinoma and cervical clear cell carcinoma [2]. Excep-
tionally, the primary site of origin remains unclear [1,4].
However, they are most frequently associated with benign
conditions, presumably related to the use of an intrauter-
ine device (IUD) [11-13], to a history of oral contracep-
tion [14] or associated with a benign ovarian neoplasm
[15], inflammatory lesions, such as tubo-ovarian adhe-
sions and endosalpingiosis [16,17], endometrial benign
hyperplasia and endometrial polyps [3]. The most reliable
predictor of a malignancy is the association of malignant
cells with PBs on the smears. The purpose of our work is
to determine the prevalence and significance of PBs in a
sequential series of CVS in the screening population of
Trento district (Italy). Furthermore, we illustrate the first
case report, as far as we are aware, of a bilateral primary
ovarian psammocarcinoma (PC), in which PBs found in
association with malignant cells in the cervicovaginal and
endometrial smears represent the first manifestation of
disease.
Methods
We identified from the computerized pathology database
of Rovereto Hospital all cases describing the presence of
PBs in CVS, with a retrospective review of 201,231 screen-
ing cytological exams from 1993 to 2006. The cervical
cancer screening program was performed according to
Walton report [18] and cytological diagnoses were
reported according to the Bethesda System and its modifi-
cations in the years [19,20]. The diagnostic connotations
were recorded using standardized Systematized Nomen-
clature of Medicine coding (PBs: M-55580). Clinical
informations were obtained from retrospective review of
women's medical records before and after identification
of PBs (age, gravity, parity, menopausal status, symptoms
present at the time of abnormal papanicolau smear, con-
traceptive and gynaecological history). Follow up infor-
mations were collected from the time of cytological
diagnosis to May 31st, 2007. Adequate diagnostic proce-
dures (endometrial aspiration, hysteroscopy, uterine
curettage, vaginal and abdominal ecography, TC) were
performed in order to identify the source of PBs.
Results and Discussion
In the retrospective review of 201,231 screening program
cytology reports we identified 6 Papanicolaou smears
with PBs (0.0029%).
Four of them belonged to premenopausal women and
PBs were found in absence of atypical cells (Fig 1a).
Endometrial aspiration was negative either for PBs or for
malignant cells.
Two of these patients (40 years old, gravida 2 para 2 and
36 years old, gravida 1 para 1) had an IUD. Because of a
possible coexistence of a gynaecologic malignancy the sur-
geons performed a laparoscopy with removal of the IUD.
The abdominal and pelvic organs, including the ovaries,
revealed no abnormalities.
The third patient (46 years old, gravida 1 para 2) showed
multiple, small cysts in the right ovary. A laparoscopic
resection was performed and histological examination
revealed benign inclusion ovarian cysts with intraparietal
PBs.
In the fourth patient (45 years old, gravida 1, para 1), a
pelvic ultrasonography showed a cystic structure, 1.5 cm
in diameter, in the right ovary. For not specified circum-
stances, an abdominal hysterectomy with bilateral salp-
ingo-oophorectomy and appendicectomy was performed.
Histopathologic examination revealed a serous cystoad-
enofibroma with PBs of the right ovary (Fig 1b). The left
ovary had no significant lesions.
Papanicolau smears were repeated three to six months
after the initial identification of PBs in the four patients,
and none of them showed persistent PBs in the smears,
even after a follow up period of 3–8 years.
The last two patients with PBs on the smears had a bilat-
eral ovarian malignancy with a diffuse involvement of the
abdominal cavity. Rare blue-stained, laminated, calcified
bodies, identified as PBs were found in association with
diagnostic malignant cells, which were variable in size
and shape and had large nuclei with prominent nucleoli
(Fig 2a). Both endometrial aspirations contained several
a) Presence of a psammoma body in absence of atypical cells  in cervicovaginal smear (Papanicolaou stain, 200×) Figure 1
a) Presence of a psammoma body in absence of atypical cells 
in cervicovaginal smear (Papanicolaou stain, 200×); b) Serous 
ovarian cystoadenofibroma with parietal psammoma bodies 
(Hematoxylin and Eosin, 100×).CytoJournal 2008, 5:7 http://www.cytojournal.com/content/5/1/7
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PBs isolated or surrounded by clusters of columnar cells
showing a moderate degree of atypia (Fig 2b). Rare papil-
lary groups of atypical glandular cells were present. Both
patients underwent an exploratory laparotomy, with a
subsequent total abdominal hysterectomy, bilateral salp-
ingo-oophorectomy, omentectomy, regional lym-
phadenectomy and multiple peritoneal biopsies.
In one patient (56-years-old, gravida 2, para 2) a preoper-
ative vaginal ultrasonography revealed a dishomogeneous
uterine corpus, 7,3 × 5,4 cm in size, with multiple nodular
lesions referable to leiomyomas located in the anterior
wall of the myometrium. Intraoperatory findings showed
a right ovarian mass, white and firm, 4 cm in diameter and
another nodular lesion on the surface of the left ovary,
grey-white, well circumscribed and 2 cm in diameter. The
invasive thickness of the ovarian stroma was 1,2 cm on
the cut surface. The omentum and peritoneal surface were
involved by multiple tumor nodules (2 cm in maximum
diameter). Intraoperative histological examination was
consistent with the diagnosis of bilateral moderately dif-
ferentiated ovarian serous adenocarcinoma. The final
pathologic report confirmed the diagnosis made on fro-
zen sections. Additonal feature was the presence of multi-
ple psammomatous calcifications (Fig 3a). Neoplastic
infiltration was observed in the endometrium, without
myometrium invasion. The omental nodules showed the
features of invasive implants. Malignant cells and PBs
were found in the peritoneal washing. Twenty-seven
regional lymph nodes were free of malignancy. She was
placed in the International Federation of Gynecology and
Obstetrics (FIGO) stage III B. The patient received chemo-
therapy. Since then, she has been followed up with several
CT scans of abdomen and pelvis and has recovered with-
out incident.
In the other patient (50 years-old, gravida 1, para 1)
exploratory laparotomy showed a diffuse white-grey nod-
ularity on the surface of both ovaries. Two omental and
three peritoneal nodules (2 cm in maximum diameter)
were found. Intraoperative histological examination was
consistent with the diagnosis of bilateral ovarian serous
carcinoma with extensive psammoma bodies formation,
showing the typical proliferative pattern of PC, according
to the diagnostic criteria defined by Gilks [21], and infil-
trating the ovarian stroma (invasive tickness > 1 cm) (Fig
3b). The nodules removed from the peritoneal and omen-
tal surfaces were confirmed to be neoplastic involvement
(Fig 3c). The final histological diagnosis was primary
bilateral psammocarcinoma of the ovaries with macro-
scopic omental and peritoneal metastases, invasion of
both tubaric lumens (Fig 3d), extension to endometrium
without myometrium infiltration. The eighteen lymph
nodes sampled were free of disease. She was placed in the
FIGO stage III B. Following surgery no gross tumor was
remaining. The peritoneal cytology was positive. The
patient was started on chemotherapy. After 10.5 years of
follow up the patient is alive, free of disease.
The prevalence of PBs in our series of consecutively
screened Papanicolau smears is 6 per 201,231 (0.0029%),
which confirms that this is a very unusual finding, in
agreement with other large series of CVS previously
a) Psammoma body surrounded by atypical cells (arrows) in  cervicovaginal smear (Papanicolaou stain, 200×) Figure 2
a) Psammoma body surrounded by atypical cells (arrows) in 
cervicovaginal smear (Papanicolaou stain, 200×); b) Psam-
moma body surrounded by atypical cells (arrows) in 
endometrial aspiration smear (Papanicolaou stain, 200×).
a) Moderately differentiated ovarian adenocarcinoma with  psammoma bodies infiltrating the stroma (Hematoxylin and  Eosin, 100×) Figure 3
a) Moderately differentiated ovarian adenocarcinoma with 
psammoma bodies infiltrating the stroma (Hematoxylin and 
Eosin, 100×); b) Psammocarcinoma localized on the ovarian 
surface with invasion of the underlying stroma (Hematoxylin 
and Eosin, 100×); c) Omental metastasis of psammocarci-
noma (Hematoxylin and Eosin, 100×); d) Presence of psam-
mocarcinoma in the tubaric lumen (Hematoxylin and Eosin, 
100×).CytoJournal 2008, 5:7 http://www.cytojournal.com/content/5/1/7
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reported in the literature and summarized in Table 1. The
actual prevalence and significance of PBs in CVS in a cer-
vical cancer screening program, based on the Walton
report [18], have not been previously reported. The Wal-
ton report, a document of the Canadian task force on cer-
vical cancer screening, recommended a program based on
chronologic age, calling for 3- and 5-year intervals
between examinations. The six cases described in our
study exhibit different clinical diagnoses, with a higher
prevalence of benign lesions associated with PBs, accord-
ing to the literature data.
The observation of PBs on CVS should not be ignored and
should alert the clinician in order to evaluate the possibil-
ity of a coexistent carcinoma, even though a review of the
literature reveals that in more than 50% of patients PBs
are associated with benign conditions [1-6]. All benign
cases are described in relatively young individuals, the
oldest being 46 years old. In two of our cases the presence
of IUD was considered the source of PBs on the basis of
similar, well documented reported cases [11-13]. Another
source of PBs in cervicovaginal smears are benign inclu-
sion cysts [22], like in another case of ours. The rupture of
an ovarian cyst, followed by aspiration of its contents and
of minute parietal fragments with PBs by the fallopian
tube is the most likely explanation for the cytological find-
ing. Calcifications and PBs are present in almost the 30%
of ovarian cystoadenofibromas [23] and this can justify
the presence of PBs in CVS, like in the fourth benign case
of ours; the same mechanism above described may be
evoked.
When PBs in the CVS are associated with malignant or
borderline tumors, the ovary is the most common pri-
mary site (51%), serous cystoadenocarcinoma being the
most common neoplasm, followed by the uterine corpus
(30%) [24]. In our two cases, the presence of malignant
cells with PBs in the lumen of the fallopian tubes may be
the mechanism responsible for the cytological findings. In
one of them, the report was related to an unknown pri-
mary bilateral ovarian PC. This represents a rare invasive
variant of serous carcinoma arising in the ovary and in the
peritoneum [21,25-31].
In the first description by Gilks et al. [21], eight cases were
primary ovarian neoplasms and three were arising from
omentum. These authors reported the accurate strict his-
tological diagnostic criteria for the diagnosis of PC,
according to which psammoma bodies must replace at
least 75% of the papillae, cytological features must be low
grade and the neoplastic epithelium must be arranged in
small nests with no areas of solid proliferation. Potential
mechanisms responsible for the characteristic, extensive
PBs formation include the accumulation of successive lay-
ers of calcium on single necrotic or degenerated tumor
cells [32].
Primary peritoneal PC is a very unusual variant of extrao-
varian neoplasms that histologically resemble surface-epi-
thelial-stromal tumours of ovarian origin.
In these cases, an adequate sampling of the omentum, the
adnexa, and the uterine serosa, as well as of any dominant
mass, is required to establish the primary origin of the
malignancy.
In our case, a stromal invasion with tumor size more than
5 × 5 mm in diameter and the extensive involvement of
the ovary surface have been considered the conclusive cri-
teria of primary bilateral ovarian PC.
Clinical behaviour of PCs closely resembles that of bor-
derline serous tumours with a protracted course and a
favourable prognosis. Nevertheless, tumors with an
aggressive course have been described in the literature
[30,31]. In the case reported by Poggi et al. [30] no adju-
vant therapy was proposed because of the supposed indo-
lent behaviour, with a recurrence of disease after eighteen
months. In the second case described by Akbulut et al.
[31], 9 cycles of chemotherapy were performed, after a
Table 1: Prevalence of psammoma bodies in cervicovaginal smears in large series studies
Authors Number of cases PBs in smears Prevalence (%)
Nicklin et al. 4,685,454 22 0,00047
Parkash et al. 82,480 8 0,0096
Muntz et al. 400,255 25 0,0062
Kern et al. 234,318 7 0,0030
De Peralta-Venturina et al. 421,358 24 0,057
Zreick et al. 34,816 18 0,052
Our study 201,231 6 0,0029
Tot. 6,059,912 110 0,0018CytoJournal 2008, 5:7 http://www.cytojournal.com/content/5/1/7
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complete debulking, with a recurrence of the disease after
5 years and metastatic infiltration of the vertebral corpus
one year later, in spite of other 6 cycles of chemotherapy.
Our patient chose to receive adjuvant chemotherapy and
is alive and free from disease after 10.5 years of follow-up.
The excellent prognosis is in agreement with previous
reports.
Conclusion
Our study performed on a large screening series confirms
that the presence of PBs in CVS is a rare finding, more
often associated with benign conditions. Anyway, this
finding should never be underestimated and a careful
examination of the morphological features of the cell
groups is crucial to establish the source of PBs and dis-
close an underlying malignancy. Additional clinical inves-
tigations are always recommendable.
Moreover, we have described the first report of ovarian PC
in which the presence of malignant cells and PBs in the
cervicovaginal and endometrial smears represents the first
manifestation of the disease.
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